- Details
- In this conversation with Alicia Morgans, Rafee Talukder and Petros Grivas share data that investigates comparing the outcomes in patients who received prior intravesical BCG, and those patients who progressed and then required immune checkpoint inhibitors, to see if prior BCG therapy had an effect on the response on immune checkpoint inhibitors. Their hypothesis was, that patients who received BC...
|
- Details
- Sam Chang and Robert Dreicer delve into the evolving landscape of adjuvant trials for urothelial carcinoma. Dr. Dreicer discusses three pivotal studies: IMvigor010, CheckMate 274, and AMBASSADOR, each exploring different drugs like atezolizumab, nivolumab, and pembrolizumab in high-risk patient populations. While IMvigor010 showed negative results, CheckMate 274 demonstrated a disease-free surviva...
|
- Details
- Ashish Kamat hosts Alexander Wyatt to discuss the role of circulating tumor DNA (ctDNA) in the clinical management of urothelial carcinoma, especially in metastatic cases. Dr. Wyatt highlights ctDNA's utility in cancer screening, residual disease detection, and therapy monitoring. Data indicates that higher levels of ctDNA often correlate with worse disease prognosis. The conversation also explore...
|
- Details
- Scott Tagawa joins Sam Chang to highlight the key topics of his discussion at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022. Dr. Tagawa provided a clinical perspective on antibody-drug conjugates in the treatment of urothelial carcinoma. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourin...
|
- Details
- Alicia Morgans interviews Simon Crabb about the ATLANTIS trial. This UK-based, investigator-led study focuses on the use of rucaparib in advanced urothelial carcinoma patients who have undergone first-line chemotherapy. The trial employs biomarker analyses to determine patient eligibility, specifically looking at DNA repair efficiency. The primary endpoint, progression-free survival, showed a sign...
|
- Details
- Sam Chang is joined by Deborah Kaye to discuss the "best papers" in urothelial carcinoma that she highlighted for her presentation at the GU ASCO 2022 Annual Meeting. She highlights four papers on urothelial carcinoma that she selected based on their clinical relevance and how they have a direct impact on bladder cancer patients today. Biographies: Deborah Kaye, MD, MS, Urologic Oncologist, Assist...
|
- Details
- At the 2022 ASCO GU meeting, Stephen Boorjian chaired a rapid abstract session in urothelial carcinoma focusing on three broad topics in advanced urothelial cancer. One abstract covers the role of neoadjuvant chemotherapy with gemcitabine and cisplatin, for patients with upper tract urothelial carcinoma. One abstract covers maintenance therapy with a checkpoint inhibitor, for patients who've not e...
|
- Details
- In this conversation with Sam Chang, Tracy Rose shares highlights from her GU ASCO 2022 presentation on novel therapies in bladder cancer and their toxicities, discussing the future of adjuvant and neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC). Biographies: Tracy L. Rose, MD, Assistant Professor of Medicine, Division of Oncology, The University of North Carolina at Ch...
|
- Details
- Sam Chang hosts Yohann Loriot to discuss the LEAP-011 study. The study aims to evaluate the combination of pembrolizumab and lenvatinib for treating metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy. Despite promising preliminary data from the KEYNOTE-146 study, the LEAP-011 trial finds no significant difference in progression-free survival (PFS) or overall su...
|
- Details
- Ashish Kamat hosts Guru Sonpavde to discuss key findings from the GU ASCO symposium. Dr. Sonpavde reviews a range of groundbreaking studies, emphasizing the potential of systemic therapy for metastatic bladder cancer. Noteworthy trials include TROPHY-U-01, which shows a 34% response rate combining sacituzumab govitecan with pembrolizumab, and a study on neoadjuvant enfortumab vedotin revealing a 3...
|
